Sanctuary Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Sanctuary Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,230	Closed	-$16.2K	–	2651
2024 Q2	$16.2K	Buy	+1,230	New	+$14.7K	﹤0.01%	2314

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SWM

Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

Sanctuary Advisors's TCRT Position: Q3 2024 in Review

Sanctuary Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2024, closing a stake of 1,230 shares — an estimated $16.2K sold.

Sanctuary Advisors first reported a position in TCRT in Q2 2024 and held it in 1 quarter. The position peaked at $16.2K in Q2 2024. 29 funds tracked by Wall St. Rank hold TCRT as of Q3 2024.

Sanctuary Advisors reported no remaining Alaunos Therapeutics position as of Q3 2024 after selling out during the quarter.
Sanctuary Advisors sold 1,230 Alaunos Therapeutics shares in Q3 2024, an estimated $16.2K.
Sanctuary Advisors first reported a position in Alaunos Therapeutics in Q2 2024 and held it in 1 quarter.
Sanctuary Advisors's Alaunos Therapeutics position peaked at $16.2K in Q2 2024.
29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2024.

Based on Sanctuary Advisors's 13F filing for Q3 2024, filed 25 Nov 2024.